12.32% -0.0655

AEON Biopharma Inc. (AEON)

개요 뉴스 가격 이력 토론 예측

Relative Volume:

AEON Biopharma Inc. Stock (AEON) Company Profile

AEON Biopharma Inc.

Healthcare (1162)

Biotechnology (673)

(949) 354-6499

5 Park Plaza, Suite 1750, Irvine

최신 SEC 제출 서류

AEON's Discussions on Twitter

AEON을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
AEON AEON Biopharma Inc.	0.466	4.91M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	474.62	121.88B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	573.45	62.69B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	555.11	33.86B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	235.74	30.51B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	238.51	25.69B	3.81B	-644.79M	-669.77M	-6.24

AEON Biopharma Inc. Stock (AEON) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2023-08-18	개시	H.C. Wainwright	Buy

AEON Biopharma Inc. 주식(AEON)의 최신 뉴스

AEON Biopharma Inc. (AEON) 재무 분석

AEON Biopharma Inc. (AEON)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.

AEON Biopharma Inc. (AEON)

AEON Biopharma Inc. Stock (AEON) Company Profile

AEON을(를) 다른 주식과 비교

AEON Biopharma Inc. Stock (AEON) Upgrades & Downgrades

AEON Biopharma Inc. 주식(AEON)의 최신 뉴스

AEON Biopharma’s Strategic Progress and Financial Turnaround - TipRanks

AEON Biopharma announces leadership change amid growth strategy By Investing.com - Investing.com Philippines

Aeon Biopharma CEO to Step Down Next Week - Orange County Business Journal

AEON Biopharma CEO Marc Forth to Resign; Board Chairman Jost Fischer Is Interim CEO - MarketScreener

AEON Biopharma announces leadership change amid growth strategy - Investing.com

AEON Biopharma Announces CEO Resignation and Interim Appointment - TipRanks

AEON Biopharma Announces CEO Transition - The Manila Times

Leadership Shift at AEON Biopharma: CEO Exit Won't Delay Critical FDA Timeline - Stock Titan

AEON Eyeing FDA Meeting On Botox Biosimilar By The End Of 2025 - News & Insights

12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga

AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times

AEON Biopharma, Inc. Advances Biosimilar Development for ABP-450 with FDA Meeting Planned for 2025 - Nasdaq

AEON's $20M Cash Injection Powers Game-Changing BOTOX Alternative Development - Stock Titan

AEON Biopharma (NASDAQ:AEON) Stock Price Down 7.6% – Should You Sell? - Defense World

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Understanding AEON’s financial ratios: A beginner’s guide - US Post News

AEON Biopharma Releases New Corporate Presentation - TipRanks

AEON Biopharma : Corporate Presentation -March 10, 2025 at 06:26 am EDT - Marketscreener.com

AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference - The Manila Times

AEON CEO to Showcase Botulinum Toxin Pipeline at Major Healthcare Conference - StockTitan

AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - Asianet Newsable

Cervical Dystonia Market Expected to Experience Major Growth - openPR

AEON stock touches 52-week low at $0.76 amid market shifts - Investing.com

AEON Biopharma, Inc. Deloitte, Inc. Announces Update of Phase 2 Double Blind Study of ABP-450 in the Treatment of Migraine - Marketscreener.com

AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine -May 03, 2024 at 07:00 am EDT - MarketScreener

AEON Biopharma, Inc. Announces Executive Changes -May 16, 2024 at 04:28 pm EDT - MarketScreener

AEON Biopharma, Inc. Announces Strategic Reprioritization to Pursue A Biosimilar Pathway for ABP-450 - Marketscreener.com

AEON Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - MarketScreener

AEON Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com

Stock market news: AEON Biopharma plummented by 65.33% while Enveric Biosciences skyrocketed by 90.68% during midday trading - Business Upturn

Stock market today: AEON Biopharma plunged by 63.17% while Enveric Biosciences surged by 124.66% in early trading - Business Upturn

AEON Biopharma To Implement 1-for-72 Reverse Stock Split For Compliance With NYSE Rules - Nasdaq

AEON Biopharma, Inc. Announces Reverse Stock Split - The Manila Times

AEON Biopharma executes reverse stock split to comply with NYSE standards - Investing.com Australia

Aeon Biopharma Approves 1-For-72 Reverse Stock Split -February 24, 2025 at 02:53 pm EST - Marketscreener.com

AEON Biopharma shares plunge as it announces reverse stock split - MSN

AEON Biopharma Stockholders Approve Key Proposals - TipRanks

AEON Biopharma Announces 1-for-72 Reverse Stock Split Effective February 26, 2025 - Nasdaq

Aeon to Implement 1-for-72 Reverse Stock Split; Shares Fall - MarketScreener

AEON Biopharma Inc (AEON) Shares Down Despite Recent Market Volatility - The News Heater

Watch this stock’s price performance: AEON Biopharma Inc (AMEX:AEON) - US Post News

AEON Biopharma Receives Notice Of Non-Compliance With NYSE American Listing Standards - Nasdaq

AEON Biopharma Inc (AMEX: AEON) Could See A Rise In Prices Shortly. - Marketing Sentinel

Investor’s Delight: AEON Biopharma Inc (AEON) Closes Weak at 0.13, Down -6.93 - The Dwinnex

AEON Biopharma receives NYSE non-compliance notice - MSN

AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards - The Manila Times

Aeon Biopharma Gets NYSE American Noncompliance Notice -February 07, 2025 at 05:06 pm EST - Marketscreener.com

Aeon Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards - Marketscreener.com

AEON Biopharma Inc [AEON] Stock trading around $0.14 per share: What’s Next? - The DBT News

AEON Biopharma, Inc. Receives Notice of Non-Compliance from NYSE American Due to Stockholders' Deficit - Nasdaq

AEON Biopharma Inc Inc. (AEON) Price Performance: A Comparative Analysis with Competitors - The InvestChronicle

AEON Biopharma Inc. (AEON) 재무 분석

매출

순이익

현금흐름

주당 순 이익

AEON과 유사한 종목